Renin angiotensin-aldosterone system (RAAS) blockers usage among type II diabetes mellitus patients —A Retrospective Study
Conclusion RAAS blockers usage among T2DM patients was higher in primary care versus tertiary care settings. Majority of the patients did not receive optimal dose of RAAS blockers.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
More News: Avapro | Diabetes | Diabetes Mellitus | Dialysis | Enalapril | Endocrinology | International Medicine & Public Health | Malaysia Health | Metabolic Syndrome | Primary Care | Study